Tags : Highly Drug-Resistant Forms TB

TB Alliance Collaborates with Hongqi Pharma to Commercialize New Therapy

Shots: Hongqi to get a license to commercialize pretomanid as part of the three-drug “BPaL” regimen to treat a highly drug-resistant form of tuberculosis in People’s Republic of China The collaboration is a part of TB Alliance’s global commercialization strategy for pretomanid, complementing its previous agreement with Mylan & Macleods to commercialize pretomanid as part […]Read More